Duoning and Branca Bunús Join Forces to Transform Transfection Technology
- Duoning Biotechnology Group and Branca Bunús Ltd. have formed a strategic partnership focused on transfection reagent development.
- The collaboration will enhance biopharmaceutical development efficiency through resource sharing and teamwork.
- Both companies aim to provide innovative solutions in transient transfection processes and support various biopharmaceutical applications.
On November 5, 2024, at a press conference in Shanghai, Duoning Biotechnology Group and Branca Bunús Ltd. entered into a strategic partnership to enhance the development of transfection reagents. The collaboration aims to optimize and apply innovative solutions to improve efficiency in biopharmaceutical development through resource sharing. Branca Bunús will focus on research and performance enhancement, particularly in scientific applications involving various forms of transfections and recombinant protein production. Duoning, recognized for its comprehensive bioprocess solutions in China, will provide its extensive sales network to support this initiative. The two companies plan to establish a specialized team dedicated to optimizing transfection processes and conducting market research that will benefit both organizations' product offerings.